Key regions: Germany, United States, France, China, Canada
The demand for Anti-Hypertensive Drugs in Denmark has been increasing over the years, driven by various factors such as an aging population, unhealthy lifestyles, and rising healthcare awareness.
Customer preferences: Patients in Denmark prefer Anti-Hypertensive Drugs that are effective, affordable, and have minimal side effects. They also prefer drugs that are easy to consume and do not require frequent dosages. In recent years, there has been a growing trend towards the use of generic drugs as they are more affordable and have the same efficacy as branded drugs.
Trends in the market: The Anti-Hypertensive Drugs market in Denmark is expected to grow in the coming years due to the increasing prevalence of hypertension among the population. As per the estimates, nearly one-third of the Danish population is affected by hypertension. The market is also expected to be driven by the introduction of new drugs with better efficacy and fewer side effects. Another trend in the market is the growing use of combination therapy, which involves the use of two or more drugs to manage hypertension.
Local special circumstances: The Danish healthcare system is highly regulated, and the government plays a significant role in the pricing and reimbursement of drugs. The government negotiates prices with pharmaceutical companies to ensure that drugs are affordable for patients. Additionally, the use of electronic health records (EHRs) is widespread in Denmark, which enables healthcare professionals to monitor patients' health and prescribe drugs accordingly.
Underlying macroeconomic factors: The Danish economy has been growing steadily over the years, driven by a strong export-oriented economy and a highly skilled workforce. The healthcare sector in Denmark is well-developed, and the government spends a significant amount of its budget on healthcare. The aging population is also a significant factor driving the demand for Anti-Hypertensive Drugs in Denmark. As the population ages, the prevalence of chronic diseases such as hypertension is expected to increase, leading to a higher demand for drugs.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
